Clinical Trials
8
Trial Phases
4 Phases
Drug Approvals
57
Drug Approvals
MAYNE PHARMA 5FU fluorouracil 5% w/w cream tube (394830)
- Product Name
- MAYNE PHARMA 5FU fluorouracil 5FU 5% w/w cream tube
- Approval Date
- Mar 6, 2024
Kapanol 200mg Retardkapseln (419970)
- Product Name
- Kapanol 200mg Retardkapseln
- Approval Date
- Aug 25, 2023
Kapanol 200mg Retardkapseln (419971)
- Product Name
- Kapanol 200mg Retardkapseln
- Approval Date
- Aug 25, 2023
FABIOR tazarotene 0.1% w/w foam aerosol can (364526)
- Product Name
- FABIOR tazarotene 0.1% w/w foam aerosol can
- Approval Date
- Nov 2, 2022
Diltiazem hydrochloride ER Capsules 120mg (396804)
- Product Name
- Diltiazem hydrochloride ER Capsules 120mg
- Approval Date
- Sep 30, 2022
Diltiazem hydrochloride ER Capsules 90mg (396803)
- Product Name
- Diltiazem hydrochloride ER Capsules 90mg
- Approval Date
- Sep 30, 2022
Diltiazem hydrochloride ER Capsules 60mg (396805)
- Product Name
- Diltiazem hydrochloride ER Capsules 60mg
- Approval Date
- Sep 30, 2022
NEXTSTELLIS estetrol (as monohydrate) 14.2 mg / drospirenone 3 mg tablet blister pack (341876)
- Product Name
- NEXTSTELLIS estetrol (as monohydrate) 14.2 mg / drospirenone 3 mg tablet blister pack
- Approval Date
- Nov 26, 2021
MAYNE PHARMA ANTIBACTERIAL HAND SANITISER GEL ethanol 80% v/v bottle (352115)
- Product Name
- MAYNE PHARMA ANTIBACTERIAL HAND SANITISER GEL ethanol 80% v/v bottle
- Approval Date
- Dec 22, 2020
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Mayne Pharma International Pty Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT03992261
- Locations
- 🇺🇸
Investigative Site 2, Hialeah, Florida, United States
🇺🇸Investigative Site 1, Saint Joseph, Missouri, United States
🇬🇪Investigative Site 9, Batumi, Georgia
A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis
- Conditions
- Lamellar Ichthyosis
- Interventions
- Drug: CD5789 Cream VehicleDrug: CD5789 Cream 100 µg/gDrug: CD5789 Cream 200 µg/g
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Mayne Pharma International Pty Ltd
- Target Recruit Count
- 65
- Registration Number
- NCT03738800
- Locations
- 🇺🇸
TCR Medical Corporation, San Diego, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Yale University, New Haven, Connecticut, United States
A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice
- Conditions
- Head Lice
- Interventions
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2020-09-17
- Lead Sponsor
- Mayne Pharma International Pty Ltd
- Target Recruit Count
- 296
- Registration Number
- NCT03337490
- Locations
- 🇺🇸
Site 105, Dinuba, California, United States
🇺🇸Site 104, Miami, Florida, United States
🇺🇸Site 101, Plantation, Florida, United States
Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies.
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- Mayne Pharma International Pty Ltd
- Target Recruit Count
- 140
- Registration Number
- NCT02978508
- Locations
- 🇺🇸
LCC Medical Research Institute, Miami, Florida, United States
🇺🇸Southcoast Research Center, Miami, Florida, United States
🇺🇸Mid Columbia Research, Richland, Washington, United States
Bioavailability Study of Lozanoc™ 65 mg Itraconazole Capsules in Patients Requiring Prophylaxis
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2018-10-26
- Lead Sponsor
- Mayne Pharma International Pty Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT02755857
- Locations
- 🇦🇺
St Vincent's Hospital, Darlinghurst, New South Wales, Australia
- Prev
- 1
- 2
- Next